JP6713719B1 - Functional food and method of ingesting functional food - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a functional food having an effect of increasing LDL cholesterol. [Solution] A functional food comprising raw liver oil derived from deep-sea shark and β-hydroxyβ-methylbutyrate (HMB) and having an effect of increasing LDL cholesterol. It is preferable to contain β-hydroxyβ-methylbutyrate in an amount of 0.3 to 1.2 relative to 1 part of raw liver oil in a weight ratio. Further, it is preferable to contain L-glutamine and L-arginine in addition to raw liver oil and HMB. In the production, first, crude oil obtained from the liver of Aishark is separated into an oil component and a solid component using a centrifuge, and impurities in the oil component are removed by filtration. After that, the component ratio of the oily component is measured to adjust the components. The components are adjusted so that the component ratio of squalene is 78 to 83 wt% and the component ratios of squalane, squalamine, and ω3 fatty acids (such as DHA and EPA) other than squalene are 17 to 22 wt %. After this, HMB is added to make a functional food. [Selection diagram] Fig. 3

Description

TECHNICAL FIELD The present invention relates to a deep sea shark, in particular, a functional food derived from raw liver oil of azame, which has an effect of increasing LDL (low density lipoprotein) cholesterol, and a method for ingesting the same.

Cholesterol (C ₂₇ H ₄₆ O) is one of the lipids along with neutral fats (triglycerides), phospholipids and free fatty acids.
Cholesterol is produced in organs and exists in the blood in the form of complex lipids (lipoproteins) that are bound to proteins and sugars. Complex lipids (lipoproteins) are divided into VLDL (very low density lipoprotein), LDL (low density lipoprotein) and HDL (low density lipoprotein) according to their specific gravity, and cholesterol is abundant in LDL and HDL. The cholesterol contained in is referred to as LDL cholesterol, and the cholesterol contained in HDL is referred to as HDL cholesterol.

Adhesion of LDL cholesterol in blood to the wall of blood vessels causes arteriosclerosis, myocardial infarction, cerebral infarction, and arterial occlusion of lower limbs, while HDL cholesterol is said to have a function of removing LDL cholesterol accumulated in tissues. .. Therefore, the former is said to be bad cholesterol and the latter is said to be good cholesterol. Cholesterol-lowering agents such as statins are commercially available to lower the LDL cholesterol level, and the smoothness of blood is said to be good for health.

For example, Patent Document 1 proposes to administer a GLP-1 compound and an anti-dyslipidemic drug in order to lower LDL cholesterol, as a treatment method for dyslipidemia caused by hyperglycemia and the like. As the anti-dyslipidemic drug, a squalene synthase inhibitor is mentioned. Here, squalene becomes cholesterol through several processes.

Patent Document 2 proposes a processed food product of squalene containing coenzyme Q10 at a high level (0.1 to 10%). Specifically, the deep sea shark liver is subjected to crushing, separation, and filtration treatment, and the components are measured to divide it into liver oil having a squalene content of 20 to 50% and liver oil having a squalene content of 50 to 80%. After mixing these liver oils, coenzyme Q10 is added.

In Patent Document 3, as a method for producing deep-sea shark liver oil, which is basically the same as that in Patent Document 2, deep-sea shark liver is crushed into a paste at low temperature, and further fixed with a liquid component by a cooling centrifuge. It is disclosed that components are separated, impurities in the obtained oily liquid component are removed by a filtration unit, and oxygen is removed in an antioxidant treatment tank.

In Patent Document 4, the shark liver is heated in a gas phase at 65° C. to 70° C. to drip off the oil, and the dropped oil is collected in a saline solution or a glycerin solution, and the oil is saline solution or A production method is described in which the desiccant is separated from the glycerin solution, and then the oil is sufficiently contacted with a desiccant of an inorganic salt composed of a strong acid and a strong base to remove water in the oil and the desiccant is separated.

On the other hand, recently, the risk of lowering cholesterol levels has been pointed out. Patent Document 5 describes that by ingesting 100 to 2000 mg of squalene orally for 4 weeks, the blood total cholesterol was increased without an increase in LDL cholesterol and neutral fat.

In Non-Patent Document 1, as a role of cholesterol, (1) Cholesterol serves as a material for cell membranes and intracellular membranes of all cells. In particular, the brain and nerves require large amounts of cholesterol. (2) It becomes a material for male and female hormones and anti-stress hormones. (3) Bile acid that is resynthesized in the liver and digests fat. Points are listed.
Further, in Non-Patent Document 1, LDL cholesterol biosynthesized in the liver is transported in the blood to remake the cell membrane, and HDL cholesterol recovers old cholesterol and excess cholesterol from cells throughout the body and returns them to the liver. It is described to reuse.

Non-Patent Document 2 shows that the higher the cholesterol level is, the lower the mortality rate is. Even if the statin drug lowers the LDL cholesterol and increases the HDL cholesterol, death of cardiovascular disease, heart attack, and stroke are reduced. It states that it could not be done.

Non-Patent Document 3 shows that (1) antiulcer action, (2) antitumor action, (3) synergistic action with an antibiotic in an antifungal action, as a result of administration of squalene to a person with liver dysfunction, (4) Regarding the immunostimulatory action and (5) liver function improving action, and regarding the total cholesterol, "all the cases remained within the normal range throughout the treatment period, and did not cause hypercholesterolemia." Is described.

In Q14 of Non-Patent Document 4, as the influence of squalene (squalene) on the cholesterol level, a mixed administration of squalene and a drug for treating hypercholesterolemia (pravastin), a relationship between squalene alone administration and cholesterol is described. .. It is described that in each case, LDL cholesterol was lowered.

Further, Non-Patent Document 5 reports that it has a function of lowering LDL cholesterol by ingesting β-hydroxyβ-methylbutyrate (HMB) alone.

JP, 2005-518408, A JP, 2007-181408, A Japanese Patent Laid-Open No. 2002-84971 JP, 2013-14721, A JP, 2008-266306, A

"I don't need drugs for cholesterol" by Rokuro Hama Kadokawa Shoten, July 30, 2007 Proceedings of the 26th Annual Meeting of the Lipid Society of Japan S4-3 General symposium 2 "There is no point in lowering cholesterol" 2017 Lipid Nutrition Vol. 26, No. 2 "Clinical effects of squalene (samemilon) on chronic hepatitis Osamu Nakajima, Medicine and Pharmacy 11: 1 219-222 January 1984. "Squalen/Squalane Q&A50" Atsushi Kaitani CMP Japan Co., Ltd. June 30, 2006 [beta-hydroxy-beta-methylbutyrate(HMB) supplementation in humans is safe and may decrease cardiovascular risk] Nissen S et al 2000 Aug. PubMed

Non-Patent Document 1 and Non-Patent Document 2 point out the risk of lowering cholesterol levels by statin agents, but do not describe squalene for keeping cholesterol levels proper.

Non-Patent Document 3 reports that squalene was administered alone and an antitumor effect was observed, but it is said that total cholesterol remains within the normal range. There is no indication of the importance of LDL cholesterol.

Non-Patent Document 4 describes that LDL cholesterol was lowered when squalene was administered alone or when squalene and a drug for treating hypercholesterolemia (pravastin) were administered in combination.

Even if β-hydroxyβ-methylbutyrate (HMB) proposed in Non-Patent Document 5 is taken alone, no increase in LDL cholesterol is observed.

Patent Document 1 describes a drug that actively lowers LDL cholesterol, and some of other patent documents and non-patent documents point out or suggest the risk of lowering LDL cholesterol. However, it does not suggest or suggest any means for increasing LDL cholesterol.

In Patent Document 2, liver oil having a high content of coenzyme Q10 has a low content of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), and liver oil having a low content of squalene is EPA (eicosapentaene). Acid, DHA (docosahexaenoic acid) content is high, and coenzyme Q10, EPA (eicosapentaenoic acid), DHA (docosahexaenoic acid), any of the processed food with a sufficient content.
However, there is no description of an increase in LDL cholesterol. As in Non-Patent Document 4, as the administration of squalene alone causes a decrease in LDL cholesterol, in order to obtain the effect of increasing LDL cholesterol, the components mixed with squalene and the mixing ratio of the components have a large effect. Seem.

Also in Patent Document 3, in the liver of a deep-sea shark, squalene, squalamine, vitamin A, vitamin E, trace minerals, omega-3 oil-based polyunsaturated fatty acids (DHA, EPA, etc.), alkyl glycerol, etc. It is stated to contain beneficial natural substances but no mention of increased LDL cholesterol.

The smell of liver oil can be removed by the method disclosed in Patent Document 4. However, Patent Document 4 does not disclose what and how much squalene can be mixed to increase LDL cholesterol.

Patent Document 5 reports that even if squalene is orally taken, that is, squalene is taken alone, no increase in LDL cholesterol is observed.

The present inventor has made the present invention on the premise that LDL cholesterol is not cholesterol to be lowered and LDL cholesterol should be raised to an appropriate value, as in Non-Patent Documents 1 and 2.
Needless to say, it is necessary to prevent LDL cholesterol from excessively increasing in plasma to form a thrombus and inhibit the blood flow. However, if LDL cholesterol is lowered more than necessary to prevent this, cell membrane formation is inhibited. Moreover, it becomes a chronic/acute fatigue syndrome including adrenal fatigue.

Squalene is a substance that is abundant in the liver of deep-sea sharks and is the basis of cholesterol biosynthesis. However, even if squalene is purified from the liver of a deep-sea shark and administered alone, LDL cholesterol does not increase as described in Non-Patent Document 4.

The present inventors have found that LDL cholesterol is increased by simultaneously ingesting β-hydroxyβ-methylbutyrate (HMB) instead of squalene alone.
Incidentally, Non-Patent Document 5 reports that β-hydroxyβ-methylbutyrate (HMB) alone has an effect of lowering LDL cholesterol.

As described above, LDL cholesterol is transported in the blood in the form of a complex lipid bound to lipoproteins to form cell walls and bile acids. One of the raw materials of this lipoprotein is HMB, which is a deep-sea raw liver oil ( By using a functional food containing squalene) and HMB, the effect of increasing LDL cholesterol in blood was confirmed.

The preferred blending ratio of deep-sea shark raw liver oil and HMB is 0.3 to 1.2 of HMB per 1 weight of raw liver oil, but the present invention is not limited thereto.

The functional food according to the present invention may contain L-glutamine and L-arginine in addition to raw liver oil and β-hydroxyβ-methylbutyrate (HMB).
As a preferable component ratio of raw liver oil, squalene is 78 to 83 wt%, and as components other than squalene, squalane, squalamine, and ω3 fatty acids (such as DHA and EPA) are 17 to 22 wt %. The component ratio is not limited to the above range.

In addition, as a method for ingesting the functional food according to the present invention, raw liver oil derived from deep sea shark and β-hydroxyβ-methylbutyrate (HMB) are orally ingested at the same time. At this time, essential amino acids, branched chain amino acids, essential fatty acids and minerals may be orally taken at the same time. Furthermore, colloidal proteins, colloidal minerals, mycelia (mushrooms), phytochemicals and the like may be ingested together.

By ingesting the functional food according to the present invention, it is possible to suppress excessive lowering of LDL cholesterol, and also to cause excessive increase of cholesterol that causes arteriosclerosis, myocardial infarction, cerebral infarction and arterial blockage of lower limbs. First, LDL cholesterol can be maintained in an appropriate range. In addition, it is effective for improving the constitution that makes people tired easily.

The figure which showed an example of the manufacturing process of the functional food which concerns on this invention. Graph showing the initial and final LDL cholesterol values of the subjects shown in Tables (1) and (2) Graph of subjects with increased LDL cholesterol among the subjects shown in Tables (1) and (2) Of the subjects shown in Tables (1) and (2), graphs of subjects whose LDL cholesterol did not increase

First, as shown in FIG. 1, the process of producing a functional food according to the present invention separates crude oil obtained from the liver of Ai Shark into an oil component and a solid component using a centrifuge, and removes impurities in the oil component. Are removed by filtration. Then, the component ratio of the oily component is measured, and if the component is not within the predetermined range, the process is returned to the centrifugation step again, and if the component is within the predetermined range, the component is adjusted as necessary.

For the component adjustment, it is preferable that the component ratio of squalene is 78 to 83 wt% and the component ratio of squalane, squalamine, and ω3 fatty acids (such as DHA and EPA) as components other than squalene is 17 to 22 wt%, but not limited to this. is not.

Then, β-hydroxyβ-methylbutyrate (HMB) is added to raw liver oil whose components have been adjusted as necessary to prepare a functional food. β-hydroxy β-methylbutyrate (HMB) may be mixed with raw liver oil, for example in the form of CaHMB.

In addition, raw liver oil and HMB may be taken at the same time. Therefore, in addition to putting both in one capsule, raw liver oil and HMB (CaHMB) may be separately prepared and orally taken at the same time.

The results of testing the effectiveness of the above functional food are shown in (Table 1) and (Table 2) below. Table (1) is a part of a test of some items, and the test values are 30 when HDL cholesterol (HDL-C), LDL cholesterol (LDL-C) and total cholesterol (T-Cho) are selected. It is a numerical value (mg/dl) from day to 390 days (every 30 days), and Table (2) shows the first value, the last value, and the number of changes in (HDL-C), (LDL-C) and (T-Cho). , Increase/decrease rate, etc.

The ingested functional food was 6 tablets of raw liver oil (580 mg×6) and 200 mg of HMB per day. If the ratio of HMB to raw liver oil is low, the lipoprotein to which LDL cholesterol binds will be insufficient, and the LDL cholesterol that will be pumped into the blood will decrease. In addition, if the amount of HMB is too large, no effect beyond a certain level can be expected. Therefore, it is suitable to set HMB to 0.3 to 1.2 g per g of fresh liver oil.

FIG. 2 is a graph showing the initial and final LDL cholesterol values of the subjects shown in Tables (1) and (2) above, and FIG. 3 is the LDL cholesterol among the subjects shown in Tables (1) and (2) above. 4 is a graph of subjects whose LDL cholesterol did not increase among the subjects shown in Tables (1) and (2) above. In each figure, the vertical axis represents LDL cholesterol (mg/dl), and the horizontal axis represents the first and last values.

From these FIGS. 2 to 4 and Tables (1) and (2), among the 11 subjects (No. 037 to 047) who ingested the functional food according to the present invention, 8 clearly had an increase in LDL cholesterol level. And three did not increase. However, subject 046, who did not increase, did not ingest. From these, the LDL cholesterol increasing effect of the functional food according to the present invention is recognized.

It should be noted that, regardless of the increase or decrease in LDL cholesterol, the improvement of symptoms was observed in all patients. For example, even if the LDL cholesterol was lowered, if the total cholesterol value was too high for some time, the LDL cholesterol was lowered to fall within the appropriate range, thereby improving fatigue and the like.

Claims (4)

Consisting of deep-sea shark-derived raw liver oil and β- hydroxyβ -methylbutyrate (HMB), the daily intake of the raw liver oil is 3480 mg or more, and the β-hydroxyβ-methylbutyrate (HMB) is 200 mg or more, A functional food having an effect of increasing LDL cholesterol. The functional food according to claim 1, which contains L-glutamine and L-arginine in addition to the raw liver oil and β-hydroxyβ-methylbutyrate (HMB). By ingesting at least 3480 mg of the raw liver oil derived from deep-sea shark and β-hydroxyβ -methylbutyrate (HMB) at the same time per day, and at least 200 mg of the β-hydroxyβ-methylbutyrate (HMB) at the same time. A method for ingesting a functional food, which comprises increasing LDL cholesterol level. The method of ingesting a functional food according to claim 3, wherein the essential amino acids, branched chain amino acids, essential fatty acids and minerals are orally taken at the same time.

Images